Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. by Siena, Salvatore et al.
1308   Review | JNCI Vol. 101, Issue 19  |  October 7, 2009
REVIEW
 The epidermal growth factor receptor (EGFR), a member of the 
human epidermal growth factor receptor (HER) – erbB family of 
receptor tyrosine kinases, represents an important target for cancer 
treatment because its activation stimulates key processes involved in 
tumor growth and progression, including proliferation, angiogene-
sis, invasion, and metastasis. The binding of EGF or other ligands to 
EGFR initiates a mitogenic signaling cascade via several pathways, 
including the RAS – RAF – mitogen-activated protein kinase (MAPK), 
phosphatidylinositol 3-kinase (PI3K) – Akt, and phospholipase C  
pathways ( 1 , 2 ). Overexpression of EGFR is found in a range of solid 
tumor types and has been linked to poorer outcomes ( 3 , 4 ). 
 EGFR inhibitors — monoclonal antibodies targeting the extracel-
lular domain and small-molecule tyrosine kinase inhibitors — have 
expanded the range of treatment options for various solid tumors. 
EGFR-targeted monoclonal antibodies have been extensively stud-
ied in metastatic colorectal cancer ( Table 1 ), whereas tyrosine kinase 
inhibitors have thus far shown little activity in this setting ( 5 , 6 ). 
Cetuximab (ER-K0034, Erbitux, Merck-Serono KgaA, Darmstadt, 
Germany; ImClone Systems Inc, New York, NY), the ﬁ rst anti-
EGFR monoclonal antibody to be approved for clinical use for meta-
static colorectal cancer, is a chimeric mouse – human monoclonal 
antibody that has been evaluated primarily in combination with che-
motherapy ( 7 – 10 ) but also as monotherapy ( 7 , 11 , 12 ). Panitumumab 
(ABX-EGF, Vectibix; Amgen Inc, Thousand Oaks, CA), a fully 
human monoclonal antibody, has shown efﬁ cacy as monotherapy in 
chemotherapy-refractory patients with metastatic colorectal cancer 
( 13 ), and ongoing chemotherapy combination trials in earlier lines of 
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treatment have reported acceptable interim safety data ( 14 , 15 ). In 
addition, cetuximab and panitumumab have both been evaluated in 
combination with bevacizumab, a monoclonal antibody targeting the 
vascular endothelial growth factor (VEGF), plus standard ﬁ rst-line 
chemotherapy ( 16 , 17 ). However, increased toxicity and a shorter 
progression-free interval were observed in the experimental groups 
compared with the control groups. Thus, the strategy of combining 
both an EGFR inhibitor and a VEGF inhibitor with chemotherapy 
appears to be detrimental and is not being pursued further. 
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 Cetuximab and panitumumab appear to have similar efﬁ cacy, 
achieving fairly modest but clinically meaningful objective 
response rates of approximately 10% when used as monotherapy 
for chemotherapy-refractory EGFR-expressing metastatic col-
orectal cancers ( 7 , 11 – 13 , 18 ). However, panitumumab is likely to 
be less immunogenic than cetuximab because of its fully human 
composition and, indeed, panitumumab seldom gives rise to 
severe infusion reactions ( 13 ). Such events may occur in up to 
22% of cetuximab-treated patients, depending on geographical 
region ( 19 , 20 ), and appear to be commonly associated with pre-
existing speciﬁ c IgE antibodies against the oligosaccharide com-
ponent of the cetuximab molecule, galactose-  -1,3-galactose ( 21 ). 
 Positive EGFR protein expression, as determined by immuno-
histochemistry, was initially selected as an entry criterion for studies 
evaluating EGFR inhibitors on the assumption that sensitivity to 
such agents was associated with EGFR expression. However, a large 
body of evidence from patients who were treated with monoclonal 
antibodies for metastatic colorectal cancer ( 7 , 11 , 13 , 22 , 23 ) or tyrosine 
kinase inhibitors for other solid tumors ( 24 , 25 ) indicates that this 
biomarker is poorly associated with response to EGFR inhibitors in 
the clinical setting. Objective responses have been observed in 
patients with low or negative, as well as high, EGFR protein expres-
sion, as determined by immunohistochemistry. These ﬁ ndings have 
led to intense research to identify alternative predictive molecular 
biomarkers that can be used to identify patients who are most likely 
to beneﬁ t from EGFR-targeted treatment. This review discusses 
progress made toward these ends with a focus on treatment of meta-
static colorectal cancer with anti-EGFR monoclonal antibodies. 
 Literature was identiﬁ ed in PubMed and oncology conference 
databases by use of the search terms “colorectal cancer” and 
“molecular markers” and retrieved articles were evaluated by the 
authors. All fully published clinical data relating to clinical 
response to treatment with monoclonal antibodies in metastatic 
colorectal cancer were considered for inclusion, as well as key 
conference abstracts. Additional searches of the same databases 
were performed to identify suitable background information. 
 Predicting Response: Molecular Biomarkers 
 Early work exploring molecular biomarkers of response to EGFR-
targeted monoclonal antibodies (ie, cetuximab or panitumumab) as 
alternatives to EGFR protein determined by immunohistochemistry 
started in 2005 ( 26 ) and was based on retrospective analyses of 
archived tumor tissue from subsets of patients participating in clini-
cal trials. However, more recently studies have been designed to 
incorporate biomarker analysis (eg, the pivotal phase III panitu-
mumab study) ( 13 , 27 ). In general, primary tumor tissue was ana-
lyzed, although metastatic tissue was evaluated in some instances. In 
the majority of studies, cetuximab was given in combination with 
chemotherapy, which could make interpretation difficult, whereas 
to date, panitumumab has been administered almost exclusively as 
monotherapy. Although most biomarker datasets are from chemo-
therapy-refractory or relapsed patients who had received multiple 
previous lines of treatment, first-line data have recently been pre-
sented ( 28 , 29 ). Finally, it should also be mentioned that many analy-
ses were based on objective responses alone, without taking disease 
stabilization into account. 
 Markers Downstream of EGFR 
 A rapidly growing body of knowledge has indicated that growth of 
many tumors is driven by constitutive activation of signaling path-
ways downstream of the EGFR, as will be discussed below.  Figure 1 
shows the interactions between various signaling pathways involved 
in tumor proliferation and progression. Such close interactions 
between these pathways may provide “escape mechanisms” that 
allow tumors to circumvent a pathway that has been pharmacologi-
cally blocked. 
 The interlinked RAS – MAPK and PI3K signaling pathways 
( Figure 1 ) play an important role in tumorigenesis via phosphory-
lation of various proteins and transcription factors that directly 
control cell growth, differentiation, and apoptosis ( 1 , 2 , 30 ).  KRAS , 
a member of the rat sarcoma virus ( ras ) gene family of oncogenes 
(including  KRAS ,  HRAS , and  NRAS ), encodes the guanosine 
diphosphate (GDP) – and guanosine triphosphate (GTP) – binding 
protein RAS that acts as a self-inactivating intracellular signal 
transducer ( 31 ). After binding and activation by GTP, RAS 
recruits the oncogene RAF , which phosphorylates MAP2K (mito-
gen-activated protein kinase kinase)-1 and MAP2K-2, thus initiat-
ing MAPK signaling that ultimately leads to expression of proteins 
playing important roles in cell growth, differentiation, and sur-
vival. The oncogene  PIK3CA encodes the p110 subunit of PI3K, 
which can be activated via interaction with RAS proteins ( 1 , 2 , 30 ). 
 Table 1 .  Anti – epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) used for treatment of metastatic colorectal 
cancer (mCRC) 
 Agent Description Company Approved indications Investigational indications 
 Cetuximab (Erbitux) Chimeric mAb Merck-Serono KGaA, 
 Darmstadt, Germany; 
 ImClone Systems Inc, 
 New York, NY
Treatment of patients with 
 EGFR-expressing,  KRAS wild-type 
 mCRC in combination with 
 chemotherapy (EU) or irinotecan 
 in irinotecan-refractory disease (US) 
 or as a single agent in patients who 
 have failed oxaliplatin- and irinotecan-
 based therapy or who are intolerant 
 to irinotecan (EU, US)
In combination with other 
 targeted agents 
 Panitumumab (Vectibix) Fully human mAb Amgen Inc, Thousand 
 Oaks, CA
Monotherapy for fluoropyrimidine-, 
 oxaliplatin-, and irinotecan-resistant 
 EGFR-expressing mCRC with wild-
 type  KRAS 
In combination with 
 chemotherapy and/or 
 other targeted agents 
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 Mutation in  KRAS ,  BRAF , or  PIK3CA results in continuous acti-
vation of the downstream RAS – MAPK or PI3K pathways, regardless 
of whether the EGFR is activated or pharmacologically blocked. 
Such activation in turn enhances transcription of various oncogenes, 
including  MYC ,  CREB , and the gene for nuclear factor   B ( 1 , 2 , 30 ). 
 A recent population-based study of 586 patients with colon 
adenocarcinomas found mutations in  KRAS ,  BRAF , and/or  PIK3CA 
in 316 (56%) of the 586 tumors studied ( 32 ).  KRAS is the most 
commonly mutated gene in this pathway, with mutations in 
35% – 45% of colorectal adenocarcinomas; mutations in  PIK3CA 
( ≤ 20%) and  BRAF (<15%) are less common ( 32 – 37 ). Mutations in 
 PIK3CA and  KRAS or  BRAF may coexist within the same tumor 
( 32 , 36 – 38 ), but  KRAS and  BRAF mutations appear to be mutually 
exclusive ( 33 , 34 , 39 – 41 ).  KRAS mutation is thought to be an early 
event in tumorigenesis ( 42 , 43 ), and, in general, metastatic and 
primary sites have been concordant with regard to  KRAS status 
( 44 – 46 ), with only small differences having been reported ( 47 , 48 ). 
 KRAS mutations have been explored as prognostic biomarkers 
(independent of anti-EGFR monoclonal antibody treatment), but 
data are conﬂ icting, reﬂ ecting differences in datasets and method-
  
 Figure 1 .   Overview of interlinked cellular signaling pathways involved in 
the proliferation and progression of colorectal cancer. Agents targeting 
signaling proteins that have been evaluated or are currently being evalu-
ated in phase II, III, or IV clinical trials for colorectal cancer are shown. The 
epidermal growth factor receptor (EGFR) – related family of receptor 
tyrosine kinases includes human epidermal growth factor receptor 
(HER1), EGFR, or c-erbB1; HER2 or c-erbB2; HER3 or c-erbB3; and HER4 
or c-erbB4. C-MET = mesenchymal – epithelial transition factor; EGF = 
epidermal growth factor; HDAC = histone deacetylases; HGF = hepatocyte 
growth factor; IGF-1 = insulin-like growth factor-I; IGF-1R = insulin-like 
growth factor-I receptor; IR = insulin receptor; VEGF = vascular endothe-
lial growth factor; VEGF-R = vascular endothelial growth factor receptor. 
ologies and possibly tumor heterogeneity ( 32 , 43 , 49 – 54 ). 
Retrospective data from 2721 patients with colorectal cancer from 
the RASCAL (ie, the Kirsten ras in Colorectal Cancer Collaborative 
Group) study ( 43 ) indicated that  KRAS mutations may be associ-
ated with increased risk of death ( P = .002). However, in phase III 
monotherapy studies of cetuximab ( 55 ) or panitumumab ( 13 , 27 ), 
 KRAS mutations did not appear to affect outcome among patients 
receiving only best supportive care. Furthermore,  KRAS mutations 
do not appear to have a stage-speciﬁ c prognostic value: No asso-
ciation between tumor  KRAS mutations and relapse-free survival 
was observed among patients with stage II and stage III colorectal 
cancer in the Pan-European Trials in Adjuvant Colon Cancer 
(PETACC) 3 study ( 54 ). 
 KRAS Mutations.  A number of groups undertook retrospective 
testing of  KRAS status of tumors from patients with metastatic 
colorectal cancer who were treated with cetuximab or panitu-
mumab (with or without chemotherapy) ( 26 , 33 , 34 ). Lievre et al. 
( 34 ) first reported the link between  KRAS mutations and lack of 
response to EGFR-targeted monoclonal antibodies, a concept 
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previously proposed by Moroni et al. ( 26 ), based on their cohort 
study (n = 30 patients). These findings were confirmed and 
extended to  BRAF in a series of 48 patients by Benvenuti et al. ( 33 ), 
who also found that transfection of mutated  KRAS (G12V) into 
wild-type DiFi colorectal cancer cells confers resistance to cetux-
imab.  KRAS mutations have since emerged as a major predictor of 
resistance to panitumumab or cetuximab in the clinical setting. 
Studies ( 27 , 34 , 36 , 55 – 60 ) of patients receiving first and subsequent 
lines of treatment have found that those with tumors carrying 
 KRAS mutations do not respond to EGFR-targeted monoclonal 
antibodies or experience any survival benefit from such treatment. 
Indeed, the progression-free interval in patients with tumors car-
rying mutant  KRAS generally appears to be approximately half that 
of those patients whose tumors carry wild-type  KRAS ( Table 2 ). 
 The pivotal randomized phase III study of panitumumab 
monotherapy in the relapsed or refractory setting ( 13 ) was the ﬁ rst 
large study (n = 463 patients) to conﬁ rm the negative predictive 
value of  KRAS mutations ( 27 ). Biomarker analysis of primary 
tumor tissue was planned in the protocol and  KRAS analysis was 
performed in a blinded manner at a central laboratory by use of a 
 KRAS testing kit (DxS Ltd, Manchester, UK) ( 27 ). Among the 463 
patients enrolled in this study, 427 (92%) were included in the 
 KRAS analysis. Of these 427, 184 (43%) were found to have 
tumors harboring mutant  KRAS : 84 (40%) of the 208 patients 
randomly assigned to panitumumab plus best supportive care and 
100 (46%) of the 219 patients assigned to best supportive care 
alone. Among the 208 patients assigned to panitumumab, 21 
(17%) of the 124 patients in the wild-type  KRAS subgroup 
achieved objective response, whereas none of the 84 patients in the 
mutant  KRAS subgroup responded to this treatment. Median 
progression-free interval among those treated with panitumumab 
was 12.3 weeks among those in the wild-type  KRAS subgroup and 
7.4 weeks among those in the mutant  KRAS subgroup. The hazard 
ratio (HR) for disease progression or death (panitumumab vs con-
trol group) was 0.45 (95% conﬁ dence interval [CI] = 0.34 to 0.59) 
for panitumumab in the wild-type  KRAS subgroup, but there was 
no beneﬁ t of panitumumab in the mutant  KRAS subgroup (HR = 
0.99, 95% CI = 0.73 to 1.36) ( Figure 2 ). A sensitivity analysis that 
adjusted for potential bias from unscheduled assessment found 
similar results. A total of 168 (77%) of the 219  KRAS -evaluable 
patients initially assigned to the control group crossed over to 
receive panitumumab after disease progression, at a median time of 
7.1 weeks; this crossover confounded analysis of overall survival. 
Among these 168 patients, 20 (22%) of the 91 in the wild-type 
 KRAS subgroup, compared with none in the mutant  KRAS sub-
group, responded to panitumumab treatment; it is important to 
note that these results were based on local review, whereas tumor 
response in the main study was based on central review ( 27 ). 
 KRAS data from three large randomized phase II – III cetuximab 
studies have recently been published, including the ﬁ rst-line 
OPUS (ie, Oxaliplatin and Cetuximab in First-Line Treatment of 
metastatic colorectal cancer) ( 28 ) and CRYSTAL (ie, Cetuximab 
Combined With Irinotecan in First-Line Therapy for Metastatic 
Colorectal Cancer) ( 29 ) studies and the NCIC-CTG (ie, National 
Cancer Institute of Canada-Clinical Trials Group) monotherapy 
study conducted in relapsed or refractory patients or those with 
contraindications to chemotherapy ( 55 ). Data from 394 (69%) of 
the 572  KRAS -evaluable patients participating in the phase III 
NCIC – CTG trial conﬁ rmed that patients with tumors carrying 
 KRAS mutations do not beneﬁ t from cetuximab monotherapy. 
Both progression-free and overall survival were similar for the 
cetuximab and control groups in those patients with tumors carry-
ing  KRAS mutations (progression-free interval = 1.8 vs 1.8  
months [HR = 0.99, 95% CI = 0.73 to 1.35,  P = .96]; overall 
survival = 4.6 vs 4.5 months [HR = 0.98, 95% CI = 0.70 to 1.37,  P = 
.89]). However, in the subgroup whose tumors carried wild-type 
 KRAS , cetuximab treatment was associated with statistically 
signiﬁ cantly ( P < .001) longer survival than control treatment 
(progression-free interval = 3.7 vs 1.9 months [HR = 0.40, 95% 
CI = 0.30 to 0.54]; overall survival = 9.5 vs 4.8 months [HR = 0.55, 
95% CI = 0.41 to 0.74,  P < .001 ]) ( 55 ). It should be noted that 
unlike the pivotal panitumumab phase III study ( 13 ), the design of 
this study did not allow patients from the control group who had 
disease progression to cross over to monoclonal antibody treat-
ment. Final retrospective data from the OPUS and CRYSTAL 
studies indicate that the addition of cetuximab to ﬁ rst-line 
FOLFOX (folinic acid, ﬂ uorouracil, and oxaliplatin) ( 28 ) or 
FOLFIRI (folinic acid, ﬂ uorouracil, and irinotecan) ( 29 ) chemo-
therapy does not beneﬁ t patients with tumors carrying  KRAS 
mutations, although those patients can beneﬁ t from chemotherapy 
alone ( Table 2 ). Indeed, ﬁ ndings of the OPUS study indicate that 
addition of EGFR-targeted treatment to chemotherapy may even 
be detrimental in such patients ( 28 ) ( Table 2 ). 
 In the PACCE (ie, Panitumumab Advanced Colorectal Cancer 
Evaluation) study ( 16 ), adding panitumumab to bevacizumab and 
chemotherapy was associated with shortening of the progression-
free interval among patients with tumors carrying wild-type  KRAS 
(11.5 months in the chemotherapy – bevacizumab arm vs 9.8 
months in the panitumumab-chemotherapy – bevacizumab arm). In 
the CAIRO (ie, Capecitabine, Irinotecan, and Oxaliplatin trial) – 2 
study ( 17 ), addition of cetuximab to capecitabine, oxaliplatin, and 
bevacizumab as ﬁ rst-line treatment in patients with metastatic 
colorectal cancer had no effect on progression-free interval among 
those with tumors carrying wild-type  KRAS (10.6 months in the 
chemotherapy – bevacizumab arm vs 10.5 months in the combined 
cetuximab arm). However, this combination had a marked detri-
mental effect among patients with tumors carrying mutated  KRAS 
(12.5 vs 8.1 months) ( 17 ). 
 The proportion of patients bearing wild-type  KRAS tumors 
who fail to achieve either objective response or disease stabilization 
with panitumumab or cetuximab varies considerably between 
studies ( Table 2 ). Among a total of 124 patients with such tumors 
who were treated with panitumumab in the pivotal phase III study, 
45 (36%) had a best response of progressive disease ( 61 ). These 
patients had a median progression-free interval of 7.3 weeks, as 
shown by a post hoc subanalysis ( Figure 3 ). However, among 
patients with stable disease or a partial response, median progression-
free interval was 23.9 and 27.0 weeks, respectively ( 61 ). 
 It is interesting to note that in other solid tumor settings, 
EGFR inhibitors (tyrosine kinase inhibitors or cetuximab) have 
shown minimal activity in patients with pancreatic cancer ( 62 , 63 ), 
which is associated with a very high prevalence of  KRAS mutations 
(approximately 90%) ( 64 ), and in patients with lung cancer whose 
tumors carry  KRAS mutations ( 65 – 67 ). 
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 BRAF Mutations.  Recently published retrospective analysis ( 40 ) 
of 113 tumors from patients who received panitumumab or cetux-
imab in second or subsequent lines of treatment showed that those 
with tumors that carried  BRAF V600E mutations (n = 11, 10%) did 
not respond to EGFR inhibition and had statistically significantly 
shorter progression-free interval ( P = .001) and overall survival ( P < 
.001) than patients whose tumors carried wild-type  BRAF (n = 34). 
A similar pattern was observed in an analysis of 231 tumors from 
patients treated with first-line cetuximab plus capecitabine, oxalipa-
tin , and bevacizumab in the CAIRO-2 study ( 41 ). The median 
progression-free interval and overall survival were 6.6 and 15.2 
months for patients with tumors carrying mutant  BRAF (n = 28), vs 
10.4 ( P = .01) and 21.5 ( P = .001) months in those with tumors car-
rying wild-type  BRAF (n = 231). However, the response rate did not 
differ between these two patient subgroups (39% vs 48%;  P = .04). 
 Di Nicolantonio et al. ( 40 ) also demonstrated that introduc-
tion of the  BRAF  V600E allele could confer resistance to either 
cetuximab or panitumumab in wild-type  BRAF colorectal cancer 
cells. Furthermore, they showed that the multikinase inhibitor 
sorafenib may restore sensitivity to EGFR inhibitors in  BRAF -
mutated colorectal cancer cell lines. Consequently, combined 
sorafenib and cetuximab therapy is undergoing clinical evaluation 
in metastatic colorectal cancer in a National Cancer Institute –
 sponsored trial (NCT00343772;  http :// clinicaltrials . gov / ct2 / show / 
NCT00343772 ). Evaluation of EGFR-targeted antibodies in 
combination with other novel and more selective  BRAF inhibi-
tors, such as PLX-4032 and XL-281, is also warranted. 
 PTEN and PI3K.  Loss of expression of the tumor suppressor 
PTEN protein, which regulates the PI3K – Akt signaling path-
way, has been reported to confer tumor resistance to EGFR 
tyrosine kinase inhibitors in vitro ( 68 ) and has been linked to 
erlotinib resistance in patients with glioblastoma ( 69 ) and to 
trastuzumab resistance in patients with breast cancer ( 70 ). In 
vitro studies in various colon cancer cell lines have found that 
activating  PIK3CA mutations or loss of PTEN expression 
 Figure 2 .  Progression-free interval and  KRAS 
mutation status of tumor in patients with meta-
static colorectal cancer who were randomly 
assigned to treatment with best supportive care 
(BSC) alone or panitumumab (Panit) plus BSC in a 
phase III study ( 27 ).  A ) Tumors with mutant  KRAS 
status.  B ) Tumors with wild-type  KRAS status ( 27 ) 
(with permission from the American Society of 
Clinical Oncology). CI = conﬁ dence interval; HR = 
hazard ratio. 
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appeared to confer resistance to cetuximab. Cell lines that had 
mutations in  PIK3CA , or were PTEN null, and also had muta-
tions in  RAS or  BRAF exhibited the greatest resistance to cetux-
imab ( 71 ). Similarly, in the clinical setting, deregulation of either 
PIK3CA or  PTEN gene (via mutation or loss of expression;  P = .02) 
( 38 ) or PTEN protein expression loss alone ( P < .001) ( 58 ) statis-
tically significantly impaired response to cetuximab-based treat-
ment in colorectal cancer patients. Frattini et al. ( 58 ) reported 
that none of 11 patients with tumor PTEN loss responded to 
cetuximab-based treatment, whereas 10 (63%) of 16 patients 
with intact PTEN protein expression were partial responders. 
Perrone et al. ( 38 ) also noted that none of three patients with 
 PTEN mutation responded to treatment with cetuximab and 
irinotecan. In a total of 92 patients with metastatic colorectal 
cancer who were included in three biomarker analyses ( 26 , 34 , 38 ), 
nine (10%) had tumors bearing  PIK3CA mutations and only one 
responded to EGFR-targeted treatment. In a larger patient 
series (n = 110), Sartore-Bianchi et al.  ( 72 ) found that  PIK3CA 
mutations and PTEN loss in colorectal tumors were statistically 
significantly associated with lack of response to panitumumab 
(zero of 15 patients,  P = .038) or cetuximab (one of 32 patients, 
 P = .001) treatment. In the same study,  PIK3CA mutations and/
or loss of PTEN expression were negatively associated with 
progression-free interval, and loss of PTEN expression was also 
linked with poorer overall survival ( P = .005). These investiga-
tors suggested that combining mutation analysis for  KRAS and 
 PIK3CA (loss of  PTEN and/or  PIK3CA mutation) could identify 
up to 70% of patients with metastatic colorectal cancer who are 
unlikely to respond to treatment with an EGFR-targeted 
monoclonal antibody ( 72 ). Contradictory evidence was recently 
reported by Prenen et al. ( 73 ) who found no strong rationale for 
using  PIK3CA mutations as a single marker for sensitivity to 
cetuximab in chemotherapy-refractory metastatic colorectal 
cancer. Razis et al. ( 74 ) reported that normal PTEN protein 
expression was associated with a higher response rate and longer 
time to progression in patients treated with cetuximab-based 
therapy, despite a 50% response rate observed in patients who 
had lost PTEN protein expression ( 74 ). Because this study 
included patients treated with first-line cetuximab and chemo-
therapy, these findings are difficult to interpret. Further inves-
tigation and prospective data from large randomized clinical 
trials are required to confirm these findings before they can be 
integrated into clinical practice. 
 Because tumors with oncogenic  PIK3CA mutations are likely to 
be driven by PI3K as the primary source of growth, proliferation, 
and survival signaling ( Figure 1 ), the use of selective PI3K inhibi-
tors is being tested in ongoing trials. Indeed, several PI3K inhibi-
tors are progressing from preclinical development to phase I 
clinical studies. This family of compounds includes XL147, GDC-
0941, BGT226, and the pan-PI3K – mammalian target of rapamycin 
(mTOR) inhibitors XL765 and NVP-BEZ235 ( 75 ). The combina-
tion of cetuximab and the mTOR inhibitor everolimus has been 
shown to be effective in restoring growth inhibition in cetuximab-
resistant colorectal cancer cells ( 76 ). It remains to be evaluated in 
clinical trials whether concomitant inhibition of the EGFR and 
PIK3CA pathways ( Figure 1 ) will convey clinical beneﬁ t. 
 In addition, in colorectal cancer, the incidence of  PIK3CA and 
 BRAF mutations (but not mutations of  KRAS or  TP53 ) displays a 
gender bias with a higher frequency occurring in women ( 32 , 77 ). 
Thus, it could be hypothesized that female patients with metastatic 
colorectal cancer might be less likely to beneﬁ t from treatment 
with EGFR-targeted monoclonal antibodies. However, available 
clinical data do not support this hypothesis ( 17 , 27 , 29 ). 
 EGFR as a Target 
 Many technical reasons have been advocated for the lack of asso-
ciation between EGFR detection by immunohistochemistry and 
response to EGFR-targeted treatment, as discussed by Shia et al. 
( 78 ). These reasons include disparity between the form or epitope 
of EGFR detected by immunohistochemistry and that targeted by 
 Figure 3 .  Progression-free interval by 
response to panitumumab in a subgroup of 
patients with metastatic colorectal cancer 
whose tumors carry wild-type  KRAS. Data 
are from a phase III study ( 27 , 61 ). 
 by guest on June 1, 2015
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
1316   Review | JNCI Vol. 101, Issue 19  |  October 7, 2009
anti-EGFR monoclonal antibodies, as well as issues related to 
processing and handling of tumor tissue samples, such as pro-
longed storage. Immunohistochemistry is also a semiquantitative 
method that lacks a standardized scoring system and is subject to 
interobserver variation. Moreover, differences between primary 
colorectal tumors and their metastases with regard to EGFR 
expression have been reported ( 79 ), indicating that reliance on 
such biomarkers in the primary tumor to predict treatment 
response of metastatic growths may be inappropriate. 
 EGFR Affinity and Phosphorylation.  Using a specific ligand-
binding assay, Francoual et al. ( 80 ) found that many tumors con-
tain both low- and high-affinity EGFRs: 64 (78%) of 82 tumor 
specimens contained only high-affinity binding sites (median dis-
sociation constant = 0.75 nM) and 18 (22%) had both low- and 
high-affinity sites. Because immunohistochemistry-based methods 
cannot distinguish between low- and high-affinity EGFR, these 
findings may provide further explanation for the lack of correlation 
between EGFR immunostaining and clinical response to EGFR-
targeted treatment. 
 EGFR phosphorylation status may reﬂ ect the level of receptor 
utilization by the tumor. This parameter (as determined by immu-
nohistochemistry) was associated with clinical response in patients 
treated with cetuximab-based therapy. Patients with an activated 
or phosphorylated EGFR score, as indicated by an immunohis-
tochemistry-based visual score of 7 or greater, were almost twice as 
likely to have disease control (objective response or stable disease) 
than those with a score of less than 7 (100% vs 54%;  P = .05) ( 81 ). 
 EGFR Gene Status.  Activating mutations, including in-frame 
deletions and amino acid substitutions in exons 18, 19, and 21 in 
the  EGFR catalytic domain, play an important role in determining 
responsiveness to tyrosine kinase inhibitors in the lung cancer set-
ting ( 82 , 83 ). Such mutations are rare ( 26 , 84 ) or absent ( 57 , 85 ) in 
colorectal cancer tumors. Moroni et al. ( 26 ) detected one mutation 
(3.2%) among 31 patients with metastatic colorectal cancer, occur-
ring in a patient who achieved stable disease for 24 weeks with 
cetuximab and chemotherapy treatment. This missense heterozy-
gous mutation in exon 21 (Gly857Arg) affected a residue located 
within the activation loop of the  EGFR catalytic domain and was 
one amino acid away from the Leu858Arg-activating mutation that 
has been identified in patients with lung cancer who respond to 
gefitinib or erlotinib ( 86 ). At disease progression, the patient 
whose tumor had this mutation was treated with gefitinib; this 
molecular alteration in EGFR was not associated with clinical 
response because the disease progressed after 4 weeks of treatment. 
Notably, a specific polymorphism of  EGFR affecting exon 13 at 
residue 521 Arg/Arg (previously identified as residue 497, 
rs11543848) has been linked with improved overall survival in 
women with metastatic colorectal cancer (vs Lys/Lys and/or Lys/
Arg variants), although the reverse pattern was observed in men 
with this disease ( 87 ). This same polymorphism has been linked to 
cetuximab response in other studies ( 88 – 90 ). Conflicting evidence 
also exists for a polymorphism affecting the ligand of EGFR, EGF, 
at position 61 (rs4444903) ( 89 , 91 , 92 ). 
 A small proportion of colorectal tumors overexpress EGFR via 
ampliﬁ cation of the gene, which can be detected by ﬂ uorescence in 
situ hybridization (FISH) ( 93 ) or chromogenic in situ hybridization 
( 78 ). Although the intensity of protein expression was associated 
with the likelihood of gene ampliﬁ cation, immunohistochemistry 
had a low speciﬁ city (17% in primary tumors and 23% in meta-
static tumors) for predicting gene ampliﬁ cation ( 78 ). 
 When  EGFR gene copy number was evaluated by polymerase 
chain reaction, no association was found between this parameter 
and clinical outcome of panitumumab- or cetuximab-based treat-
ment ( 26 , 57 , 85 ), probably because of tumor DNA dilution by 
DNA from normal cells during DNA extraction. However,  EGFR 
gene copy number as analyzed by FISH or chromogenic in situ 
hybridization appears to be a promising biomarker of response to 
such treatment ( Table 3 ), and present technical limitations are 
being addressed in pathology studies ( 97 ). Methods of tissue pro-
cessing and  EGFR scoring systems differed between studies. 
Moreover, FISH pattern for  EGFR expression is often nonhomo-
geneous in colorectal cancer tumors, with variable ratios of disomy 
vs polysomy or ampliﬁ cation being observed ( 93 , 94 ). Increased 
gene copy number was found in at least 30% of patients when a 
threshold value of approximately three  EGFR copies per nucleus 
was used, as determined by FISH, compared with only 10% of 
patients when a threshold of six or more  EGFR copies per nucleus 
was used, as determined by chromogenic in situ hybridization 
( Table 3 ). Statistically signiﬁ cant concordance between primary 
colorectal tumors and their metastases with regard to  EGFR gene 
copy number has been found, as identiﬁ ed by FISH ( 95 , 96 ). 
 Available data suggest that patients with less than three  EGFR 
gene copies per nucleus have a relatively low likelihood of respond-
ing to EGFR-targeted monoclonal antibody treatment ( 34 , 56 , 94 –
 96 ). In a retrospective analysis of a subgroup of patients participating 
in the pivotal phase III trial of panitumumab monotherapy ( 94 ), 
the mean  EGFR gene copy number per nucleus and the percentage 
of tumor cells with chromosome 7 polysomy (three or more  EGFR 
signals per nucleus) were analyzed by FISH and the association 
between these parameters and clinical outcome was assessed. None 
of the patients with a mean of <2.47  EGFR gene copies per nucleus 
or fewer than 43% of tumor cells with chromosome 7 polysomy, 
respectively, achieved objective response compared with six (30%) 
of the 20 patients ( P = .001) and six (32%) of the 19 patients ( P = 
.001) who had values above these thresholds. A mean  EGFR gene 
copy number threshold of less than 2.5 copies per nucleus or fewer 
than 40% of tumor cells with chromosome 7 polysomy discrimi-
nated patients with shorter progression-free ( P = .039 and  P = .029, 
respectively) and overall survival ( P = .015 and  P = .014, respec-
tively).  EGFR gene copy number and chromosome 7 polysomy 
status did not draw a parallel with progression-free interval in 
patients receiving only supportive care in this study, suggesting 
that this parameter is not prognostic in metastatic colorectal can-
cer ( 94 ). These data contrast with earlier ﬁ ndings that were based 
on quantitative polymerase chain reaction analysis ( 85 ) showing 
that  EGFR gene copy number, as assessed by this method, related 
to neither clinical response nor progression-free interval. 
Homogeneous (ie, 100%) chromosome 7 disomy was the most 
common pattern found in 58 colorectal tumors with nonincreased 
gene copy number (n = 26; 45%) ( 94 ). Chromosome 7 disomy is 
easier to detect than an increase in  EGFR gene copy number and, 
therefore, might enable a more reproducible FISH assay. However, 
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methods need to be further standardized for better reproducibility 
and optimum sensitivity ( 96 , 97 ). 
 In comparison with patients with normal  EGFR gene copy num-
ber, patients with an increased  EGFR gene copy number exhibit 
higher response rates to EGFR-targeted monoclonal antibodies, 
with a longer progression-free interval or time to progression 
( 34 , 58 , 94 – 96 ) ( Table 3 ). Two studies found that six (30%) of 
20 patients and 14 (33%) of 43 patients with increased  EGFR gene 
copy number had an objective response to panitumumab ( 94 ) or 
cetuximab with or without chemotherapy ( 95 ). Such response rates 
compare favorably with historical response rates reported for popu-
lations selected by EGFR immunostaining alone. Higher response 
rates were seen in other studies ( Table 3 ). For instance, Moroni et al. 
( 26 ) found an 89% response rate in a subgroup of nine patients with 
colorectal cancer whose tumors had an increased  EGFR gene copy 
number, but these investigators included a relatively high propor-
tion of responders (nine of 29 patients; 31%) in their analysis. In 
vitro studies by these investigators also showed that the proliferation 
of various colorectal cancer cell lines with ampliﬁ ed EGFR was 
completely inhibited by cetuximab at concentrations that did not 
affect proliferation of cells with unampliﬁ ed EGFR ( 26 ). Logistic 
regression analysis indicated that the odds ratio for response to pani-
tumumab was 5.62 (95% CI = 1.51 to 21.0) for increased vs normal 
mean  EGFR gene copy number ( 94 ). 
 Overexpression of Other EGFR Ligands.  Elevated gene expres-
sion of alternative EGFR ligands, such as epiregulin and amphi-
regulin, may promote tumor growth and survival via an autocrine 
loop ( 59 , 98 ). Expression of high levels of mRNA for either epi-
regulin or amphiregulin has been associated with sensitivity to 
cetuximab monotherapy ( 59 , 98 ). Comparison of clinical outcomes 
for patients with high and low levels of these ligands showed a 
statistically significantly improved disease control rate ( P < .001) 
and longer progression-free interval among patients with high 
expression of epiregulin (median = 103.5 vs 57 days,  P < .001; 
HR = 0.47 [95% CI = 0.24 to 0.64]) or amphiregulin (median = 
115.5 vs 57 days,  P < .001; HR = 0.44 [95% CI = 0.21 to 0.57]) ( 59 ). 
The exclusive use of either  KRAS status or amphiregulin or epi-
regulin gene expression profiles ( 59 ) does not result in the selec-
tion of identical patient populations who are likely to benefit from 
treatment with cetuximab: Among patients with wild-type  KRAS , 
patients whose tumors expressed high levels of amphiregulin or 
epiregulin were likely to experience disease control, whereas 
patients whose tumors expressed low levels of these genes were 
not, thus providing important complementary information to 
 KRAS status ( 99 ). Increased gene copy number of HER2 (the pre-
ferred heterodimer of EGFR) was linked to a statistically signifi-
cantly shorter overall survival ( P = .03), with a trend toward a 
shorter time to progression ( P = .09), in 85 patients receiving 
cetuximab with or without chemotherapy ( 100 ). 
 Other Potential Biomarkers 
 Markers of angiogenesis and cell cycle regulation appear to be 
promising areas for further research. Angiogenesis is a prerequisite 
for growth and progression of tumors ( 101 , 102 ). Although driven 
by separate mechanisms, EGFR and the key angiogenic factor 
VEGF-1 share common downstream pathways ( Figure 1 ). Findings 
of preclinical studies (conducted in human tumor cell lines xeno-
grafted into murine models that evaluated the combined pharma-
cological targeting of EGFR-dependent and VEGF-dependent 
pathways) indicate direct or indirect angiogenic effects of EGFR 
signaling ( 103 – 106 ). Furthermore, expression of VEGF-1 or its 
receptor has been linked to resistance to EGFR-targeted agents in 
various cancer cell lines ( 107 ) and in patients with metastatic col-
orectal cancer ( 108 ). Markers that have been positively linked to 
outcome in patients with metastatic colorectal cancer who were 
treated with EGFR-targeted monoclonal antibodies include 
expression or gene polymorphisms of cyclooxygenase-2 ( 108 , 109 ), 
interleukin-8 ( 108 , 109 ), and the cell cycle regulator cyclin D1 
( 93 , 108 , 109 ). For instance, Vallböhmer et al. ( 108 ) concluded that 
a combination of low gene expression levels of cyclooxygenase-2, 
EGFR, and interleukin-8 was statistically significantly related to 
the overall survival of patients who were treated with cetuximab 
monotherapy (13.5 vs 2.3 months in those with high gene expres-
sion levels of these three genes;  P = .028). Feedback mechanisms 
and complex cellular circuits further link expression of VEGF, 
interleukin-8, and cyclooxygenase-2 to the oncogenic activation of 
 KRAS and  BRAF genes. For example, expression of cyclooxyge-
nase-2, an upstream regulator of EGFR activity, is driven via the 
EGFR cascade ( Figure 1 ), and in particular oncogenic  KRAS has 
been shown to induce cyclooxygenase-2 expression ( 110 , 111 ). In 
addition, increased expression of cyclooxygenase-2 may result in 
increased production of prostaglandin E2, which in turn can trans-
activate EGFR ( 112 ). Expression of the transcription factor nuclear 
factor   B has also been linked with resistance to cetuximab ( 113 ). 
 Polymorphisms in fragment c gamma receptors, surface recep-
tors for immunoglobulin G located on immune effector cells (such 
as natural killer lymphocytes and macrophages), are also of interest 
as potential markers of response to EGFR-targeted monoclonal 
antibodies, although data are conﬂ icting at present ( 109 , 114 – 116 ). 
Fragment c gamma receptors are thought to play a role in antibody-
dependent cell-mediated cytotoxicity, which has been postulated as 
an additional mechanism of action for the IgG1 type of monoclonal 
antibodies, such as cetuximab, rituximab, and trastuzumab ( 117 ). 
Although it was initially believed that panitumumab, as an IgG2 
monoclonal antibody, would not elicit antibody-dependent cell-
mediated cytotoxicity, this phenomenon has recently been demon-
strated in squamous cell head and neck carcinomas in vitro at 
concentrations that are analogous to therapeutic doses ( 117 ). 
 Molecular brakes that protect against inappropriate oncogene 
activation (such as  TP53 ) may also be candidate biomarkers of 
sensitivity to anti-EGFR therapy, given that their inactivation may 
be required for tumor progression. Indeed, Oden-Gangloff et al. 
( 118 ) suggest that  TP53 mutations may be predictive of increased 
likelihood of response to cetuximab treatment, particularly in 
patients with wild-type  KRAS status ( 118 ). 
 Early Response Evaluation 
 The characteristic “acneiform” skin rash observed in most patients 
who are treated with EGFR inhibitors has been studied as a poten-
tial marker of efficacy. This adverse effect is usually apparent after 
approximately 1 week of treatment and reaches maximum severity 
after 2 – 3 weeks. As with the tyrosine kinase inhibitor erlotinib 
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in patients with lung cancer ( 24 , 119 ), skin toxicity has been con-
sistently linked with higher response rates and longer survival 
among patients with metastatic colorectal cancer who have 
been treated with panitumumab ( 13 , 120 ) or cetuximab ( 7 , 11 , 12 ), 
whereas patients without rash appear to have a poor outcome. 
 Figure 4 illustrates the relationship between survival and worst 
grade of rash among patients treated with panitumumab ( 13 ) or 
cetuximab ( 12 ) monotherapy in two phase III studies. A landmark 
analysis (including only patients who were progression free for 
 ≥ 28 days to allow time for onset) of progression-free interval data 
from the panitumumab study (n = 231) showed a statistically sig-
nificant benefit for patients with grade 2 – 4 skin toxicity compared 
with those with grade 1 skin toxicity (HR = 0.62, 95% CI = 0.44 
to 0.88) ( 13 ). 
 Rash might indicate receptor saturation, and “dose-to-rash” 
strategies are being studied with the aim of optimizing response to 
EGFR-targeted treatment. Preliminary data from the phase I – II 
 Evaluation of Various Erbitux Regimens by means of Skin and 
Tumour biopsies (ie, EVEREST) study suggest that among patients 
receiving cetuximab-based treatment, cetuximab dose escalation to 
500 mg/m 2 per week may improve response rates in those with no or 
slight skin reactions ( 121 ), but the difference was not statistically 
signiﬁ cant and results require conﬁ rmation in a larger study. 
Subsequent analysis of results by  KRAS status showed that cetux-
imab dose escalation did not increase response in patients with 
tumors carrying a mutant  KRAS gene. However, among those with 
tumors carrying wild-type  KRAS , this strategy improved the 
response rate from four (21%) of 19 patients to 13 (46%) of 28 
patients ( 122 ). It is important to note that the panitumumab regimen 
of 6 mg/kg every 2 weeks, which is approved for treatment of meta-
static colorectal cancer, achieves similar drug exposure to a regimen 
of 2.5 mg/kg per week, which was studied in early phase trials and 
was found to be associated with a 100% incidence of rash ( 123 ). 
 There are several limitations to the use of rash as an early physi-
cal marker of efﬁ cacy. As highlighted by De Roock et al. ( 57 ), there 
are no criteria for toxic effects involving skin that are speciﬁ cally 
tailored to the activity of EGFR-targeted treatment. Rash often 
occurs in patients without apparent beneﬁ t from anti-EGFR treat-
ment, and conversely, clinical beneﬁ t has also been seen in patients 
without rash ( 124 ). Because EGFR is expressed in the skin, skin 
rash may indicate local receptor saturation, but other factors, such 
as their immune status, might alter an individual ’ s susceptibility to 
rash. An association has been observed between tumor and normal 
tissue with regard to high-afﬁ nity EGFR. This ﬁ nding might pro-
vide an explanation for the link observed between skin toxicity and 
clinical outcome of patients treated with EGFR-targeted treat-
ment ( 81 ). Moreover, the relationship between rash and clinical 
beneﬁ t is inconsistent for the tyrosine kinase inhibitor geﬁ tinib 
( 124 ) and, intriguingly, rash is not observed in patients treated 
with the humanized anti-EGFR monoclonal antibody nimotu-
zumab ( 125 , 126 ), although it should be noted that efﬁ cacy data for 
this drug are currently limited. 
 Anti-EGFR monoclonal antibody treatment may compromise 
renal magnesium retention capacity, leading to hypomagnesemia 
in some patients with colorectal cancer ( 127 ). Vincenzi et al. ( 128 ) 
recently suggested that reduction in serum magnesium levels 
might potentially provide an early marker of efﬁ cacy of combined 
treatment with cetuximab and irinotecan. It has also been sug-
gested that treatment with cetuximab may induce a sudden and 
lasting modulation of circulating VEGF levels ( 129 ), although 
the association between this ﬁ nding and clinical efﬁ cacy was not 
reported. 
 Discussion and Future Perspectives 
 Although the link between clinical benefit and overexpression of 
the molecular target is clear for trastuzumab and imatinib and their 
respective targets (HER2 and the BCR-ABL tyrosine kinase), 
experience has shown that positive expression of EGFR as shown 
by immunostaining is not predictive of response to EGFR inhibi-
tors. It is now clear that tumor growth can be driven by constitutive 
activation of signaling pathways downstream of the EGFR, such as 
the RAS – MAPK – PI3K pathway. Oncogenic activation of compo-
nents in these pathways can bypass the EGFR-driven signaling 
cascade and impair the clinical efficacy of anti-EGFR monoclonal 
antibodies. Such activation can occur via mutations in oncogenes 
such as  KRAS or  BRAF on one side of the EGFR-mediated path-
way or by  PIK3CA mutation or loss of tumor suppressor genes 
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 Figure 4 .  Probability of survival by worst grade of skin toxicity in 
patients with metastatic colorectal cancer who were treated with EGFR-
targeted monoclonal antibodies in two randomized phase III studies.  A ) 
Patients treated with panitumumab. Data are from a landmark analysis 
that was limited to patients with progression-free interval of at least 28 
days ( 13 ) (with permission from the American Society of Clinical 
Oncology.  B ) Patients treated with cetuximab ( 12 ). Reproduced with 
permission from the  New England Journal of Medicine . Copyright 2007 
Massachusetts Medical Society. All rights reserved. CI = conﬁ dence 
interval; HR = hazard ratio. 
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such as  PTEN on the opposite side of the cascade ( 72 ) ( Figure 1 ). 
These findings may provide some explanation for the rather 
modest objective response rates that have been achieved with clini-
cal trials of EGFR inhibitors to date, as well as the disparities 
observed between clinical and preclinical findings. It should also 
be noted that preclinical models are based on particular tumor 
subtypes that may not be representative of most tumors encoun-
tered in clinical practice. 
 Table 4 summarizes potential biomarkers that may be related to 
primary response to the anti-EGFR monoclonal antibodies, pani-
tumumab and cetuximab. Overall, presently available data reviewed 
in this article provide convincing evidence that activating muta-
tions of  KRAS , which are present in a substantial proportion of 
patients with metastatic colorectal cancer, predict lack of response 
to anti-EGFR monoclonal antibody treatment ( 27 – 29 ,  33 , 34 , 55 , 60 ). 
This ﬁ nding is consistent with observations from use of EGFR 
tyrosine kinase inhibitors in the treatment of non – small cell lung 
cancer, although  KRAS mutations are less common in lung tumors 
( 66 , 67 ). 
 KRAS testing is now being integrated into clinical practice. The 
European Medicines Agency’s conditional approval of panitumumab 
monotherapy in the setting of chemorefractory metastatic colorectal 
cancer speciﬁ ed wild-type  KRAS as a selection marker (134). 
Current data indicate that objective response rates of up to 22% can 
be expected in such patients (Table 2). It should be noted that clini-
cal beneﬁ t is not conﬁ ned to objective responders because delaying 
disease progression can improve clinical symptoms and the patient’s 
quality of life (135). Wild-type  KRAS was more recently identiﬁ ed 
as a selection marker for cetuximab monotherapy or combination 
therapy (136). The European Medicines Agency (20, 130), the US 
Food and Drug Administration (137), and the American Society of 
Oncology (131) now recommend determining tumor  KRAS status 
before initiating treatment with an anti-EGFR monoclonal anti-
body and restricting such treatment to patients with tumors bearing 
wild-type  KRAS . 
 Because of the complexity of the EGFR signaling system, it is 
likely that predictive algorithms will be developed for metastatic 
colorectal cancer that incorporate several molecular biomarkers. 
For instance, combining analysis of  KRAS status with determina-
tion of  BRAF and  PIK3CA status and PTEN expression may iden-
tify additional patients with metastatic colorectal cancer who are 
unlikely to respond to treatment with an EGFR-targeted mono-
clonal antibody ( 133 ). However, these additional markers ( Table 4 ) 
require further validation before they can be incorporated into 
clinical practice. 
 Tumors with an increased  EGFR gene copy number as assessed 
by FISH or chromogenic in situ hybridization may be dependent 
on the EGFR pathway for their survival and growth. There is 
evidence that normal diploid  EGFR gene copy number may predict 
tumor resistance to EGFR-targeted treatment ( Table 3 ). Again, 
further research is required to validate this biomarker in larger 
patient series ( 97 ). 
 There are clearly a number of technical issues to be overcome, 
particularly standardization of analytical methods and scoring sys-
tems. Lack of standardization may well explain some of the discordant 
results that have been reported. Certainly, some biomarkers may not 
prove suitable for translation into clinical practice. However, DNA 
sequencing of formalin-ﬁ xed parafﬁ n-embedded tumor samples is a 
relatively straightforward method for identifying  KRAS mutations. 
Because  KRAS mutation is an early event in colorectal cancer tumori-
genesis ( 42 , 43 ), archived primary tumor tissue can be used to identify 
patients who are unlikely to respond to EGFR-targeted monoclonal 
antibodies, even after multiple lines of treatment. A  KRAS testing kit 
from DxS Ltd can identify the following seven somatic mutations in 
 KRAS codons 12 and 13: Gly12Ala, Gly12Arg, Gly12Asp, Gly12Ser, 
Gly12Cys, Gly12 Val, and Gly13Asp. The polymerase chain reac-
tion – based technique used is highly sensitive but does not detect less 
frequent changes that can be detected with direct sequencing (eg, 
Gly13Val, Gly13Ala, and Gly13Cys). Although direct sequencing has 
the capability to detect all changes at the nucleotide level, it is less 
 Table 4 .  Summary of potential predictive molecular biomarkers for response to the epidermal growth factor receptor (EGFR) – targeted 
monoclonal antibodies cetuximab and panitumumab in metastatic colorectal cancer * 
 Relationship to response Biomarker First author (reference) 
 Predicts lack of response and now 
 incorporated into clinical practice † 
 KRAS mutation Amado ( 27 ); Bokemeyer ( 28 ); Van Cutsem 
 ( 29 );  Table 2 , this article; ( 20 , 130 , 131 ) 
 Very likely to predict lack of response Mutation or lack of expression of PTEN; mutation 
 of  BRAF or  PIK3CA 
Frattini ( 58 ); Perrone ( 38 ); Benvenuti ( 33 ); 
 Di Nicolantonio ( 40 ); Sartore-Bianchi ( 72 ); 
 Di Nicolantonio ( 132 ) 
 May predict lack of response ‡ Increased HER2 gene copy number Finocchiaro ( 100 ) 
 May predict increased likelihood of response Increased  EGFR gene copy number §  Table 3 , this article 
 Increased EGFR phosphorylation ‡ Personeni ( 81 ) 
 Overexpression of alternative EGFR ligands 
 (amphiregulin and/or epiregulin) ‡ 
Khambata-Ford ( 59 ) 
 pAKt overexpression ‡ Razis ( 133 ) 
 Other potential markers Markers of angiogenesis and cell cycle regulation; 
 transcription factors (VEGF, IL-8, COX-2, cyclin D, 
 NF  B) ‡ 
Vallböhmer ( 108 ); Nagashima ( 109 ); 
 Zhang ( 92 ) 
 *  Data are based on analysis of tumor tissue from patients participating in clinical trials. COX-2 = cyclooxygenase-2; HER2 = human epidermal growth factor-2; 
IL-8 = interleukin-8; NF  B = Nuclear factor kappa B; pAkt = phosphorylated Akt; VEGF = vascular endothelial growth factor. 
 †  Based on data from a study that prospectively defined biomarker analysis and included a large number of patients ( 13 ). 
 ‡  Limited preliminary data. 
 §  Data need to be confirmed in large patient datasets, preferably with prospective study design. 
 by guest on June 1, 2015
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
jnci.oxfordjournals.org   JNCI | Review 1321
sensitive and may occasionally miss mutations, especially if the frac-
tion of tumor vs normal cells is low ( 57 ). Testing will be facilitated by 
gene panel microarray technology and gene panels that incorporate 
 KRAS testing are being evaluated ( 138 ). 
 Further work is also required to explore potential early markers 
of response (in patients already receiving EGFR-targeted treat-
ment) that can be incorporated into the design of future prospec-
tive clinical trials and guide therapeutic decisions regarding 
continuation of treatment in individual patients. Skin toxicity 
develops at an early stage in treatment with EGFR inhibitors and 
has been studied extensively as a potential early marker of response, 
although further work is required. 
 Virtually all responding tumors eventually “escape” from 
EGFR-targeted treatment (ie, develop acquired resistance). In the 
lung cancer setting, acquired resistance to erlotinib or geﬁ tinib has 
been attributed to development of a secondary mutation within the 
 EGFR catalytic domain ( 139 ). Other potential escape mechanisms 
include activation of alternative signaling pathways contributing to 
proliferation and survival, such as those involving activation of 
HER2, HER3, mesenchymal – epithelial transition factor (C-MET), 
insulin-like growth factor-I receptor , MAPK, and Akt ( 140 ). 
Consequently, identiﬁ cation of the molecular basis of acquired 
resistance to anti-EGFR monoclonal antibodies in metastatic col-
orectal cancer should be a priority for future research. 
 In conclusion, the quest for predictive biomarkers of response to 
EGFR inhibitor therapy has resulted in a rapidly accumulating body 
of knowledge that has paved the way for more targeted use of these 
agents. More rational use of EGFR-targeted agents should provide 
beneﬁ ts for patients and health-care providers alike by sparing 
patients unnecessary treatment and allowing better use of health-
care resources. Prospective biomarker-driven studies are now under 
way, but in the meantime, the identiﬁ cation of wild-type  KRAS 
as a selection biomarker for panitumumab or cetuximab therapy 
represents an important step toward fulﬁ lling the promise of 
individualized treatment for metastatic colorectal cancer. 
 References 
  1.  Yarden  Y ,  Sliwkowski  MX .  Untangling the ErbB signalling network .  Nat 
Rev Mol Cell Biol.  2001 ; 2 ( 2 ): 127 – 137 . 
  2.  Scaltriti  M ,  Baselga  J .  The epidermal growth factor receptor pathway: a 
model for targeted therapy .  Clin Cancer Res.  2006 ; 12 ( 18 ): 5268 – 5272 . 
  3.  Harari  PM .  Epidermal growth factor receptor inhibition strategies in 
oncology .  Endocr Relat Cancer .  2004 ; 11 ( 4 ): 689 – 708 . 
  4.  Nicholson  RI ,  Gee  JM ,  Harper  ME .  EGFR and cancer prognosis .  Eur J 
Cancer .  2001 ; 37 ( suppl 4 ): S9 – S15 . 
  5.  Mackenzie  MJ ,  Hirte  HW ,  Glenwood  G , et al .  A phase II trial of ZD1839 
(Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine 
kinase inhibitor, in patients with metastatic colorectal cancer .  Invest New 
Drugs .  2005 ; 23 ( 2 ): 165 – 170 . 
  6.  Santoro  A ,  Comandone  A ,  Rimassa  L , et al .  A phase II randomized multi-
center trial of geﬁ tinib plus FOLFIRI and FOLFIRI alone in patients with 
metastatic colorectal cancer .  Ann Oncol .  2008 ; 19 ( 11 ): 1888 – 1893 . 
  7.  Cunningham  D ,  Humblet  Y ,  Siena  S , et al .  Cetuximab monotherapy and 
cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal 
cancer .  N Engl J Med .  2004 ; 351 ( 4 ): 337 – 345 . 
  8.  Sobrero  AF ,  Maurel  J ,  Fehrenbacher  L , et al .  EPIC: phase III trial of 
cetuximab plus irinotecan after ﬂ uoropyrimidine and oxaliplatin failure in 
patients with metastatic colorectal cancer .  J Clin Oncol .  2008 ; 26 ( 14 ):
 2311 – 2319 . 
  9.  Van Cutsem  E ,  Nowacki  M ,  Lang  I , et al .  Randomized phase III study of 
irinotecan and 5-FU/FA with or without cetuximab in the ﬁ rst-line treat-
ment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL 
trial [abstract 4000] .  J Clin Oncol .  2007 ; 25 :( suppl ). 
  10.  Bokemeyer  C ,  Bondarenko  I ,  Makhson  A , et al .  Cetuximab plus 5-FU/FA/
oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the ﬁ rst-line treatment of 
metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study 
[abstract 4035] .  J Clin Oncol .  2007 ; 25 :( suppl ). 
  11.  Saltz  LB ,  Meropol  NJ ,  Loehrer  PJ  Sr , et al .  Phase II trial of cetuximab in 
patients with refractory colorectal cancer that expresses the epidermal 
growth factor receptor .  J Clin Oncol .  2004 ; 22 ( 7 ): 1201 – 1208 . 
  12.  Jonker  DJ ,  O’Callaghan  CJ ,  Karapetis  CS , et al .  Cetuximab for the treat-
ment of colorectal cancer .  N Engl J Med .  2007 ; 357 ( 20 ): 2040 – 2048 . 
  13.  Van Cutsem  E ,  Peeters  M ,  Siena  S , et al .  Open-label phase III trial of 
panitumumab plus best supportive care compared with best supportive 
care alone in patients with chemotherapy-refractory metastatic colorectal 
cancer .  J Clin Oncol .  2007 ; 25 ( 13 ): 1658 – 1664 . 
  14.  Peeters  M ,  Wilson  G ,  Ducreux  M , et al .  Phase III study (20050181) of 
panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line 
treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): 
pooled safety results [abstract 4064] .  J Clin Oncol .  2008 ; 26 : suppl . 
  15.  Siena  S ,  Tabernero  J ,  Burkes  RL , et al .  Phase III study (PRIME/20050203) 
of panitumumab (pmab) with FOLFOX compared with FOLFOX alone 
in patients (pts) with previously untreated metastatic colorectal cancer 
(mCRC): pooled safety data [abstract 4034] .  J Clin Oncol .  2008 ; 26 :( suppl ). 
  16.  Hecht  JR ,  Mitchell  E ,  Chidiac  T , et al .  A randomized phase IIIB trial of 
chemotherapy, bevacizumab, and panitumumab compared with chemo-
therapy and bevacizumab alone for metastatic colorectal cancer .  J Clin 
Oncol .  2009 ; 27 ( 5 ): 672 – 680 . 
  17.  Tol  J ,  Koopman  M ,  Cats  A , et al .  Chemotherapy, bevacizumab, and cetux-
imab in metastatic colorectal cancer .  N Engl J Med .  2009 ; 360 ( 6 ): 563 – 572 . 
  18.  Hecht  JR ,  Patnaik  A ,  Berlin  J , et al .  Panitumumab monotherapy in 
patients with previously treated metastatic colorectal cancer .  Cancer . 
 2007 ; 110 ( 5 ): 980 – 988 . 
  19.  O’Neil  BH ,  Allen  R ,  Spigel  DR , et al .  High incidence of cetuximab-
related infusion reactions in Tennessee and North Carolina and the 
association with atopic history .  J Clin Oncol .  2007 ; 25 ( 24 ): 3644 – 3648 . 
  20.  Anonymous .  Summary of product characteristics (Erbitux) .  http ://
 www . emea . europa . eu / humandocs / PDFs / EPAR / erbitux / H - 558 - PI - en . pdf . 
Accessed July 21, 2009 . 
  21.  Chung  CH ,  Mirakhur  B ,  Chan  E , et al .  Cetuximab-induced anaphylaxis 
and IgE speciﬁ c for galactose-alpha-1,3-galactose .  N Engl J Med .  2008 ; 
358 ( 11 ): 1109 – 1117 . 
  22.  Chung  KY ,  Shia  J ,  Kemeny  NE , et al .  Cetuximab shows activity in col-
orectal cancer patients with tumors that do not express the epidermal 
growth factor receptor by immunohistochemistry .  J Clin Oncol .  2005 ; 23 ( 9 ): 
1803 – 1810 . 
  23.  Mitchell  EP ,  Hecht  JR ,  Baranda  J , et al .  Panitumumab activity in meta-
static colorectal cancer (mCRC) patients (pts) with low or negative tumor 
epidermal growth factor receptor (EGFr) levels: an updated analysis 
[abstract 4082] .  J Clin Oncol .  2007 ; 25 ( 18 )( suppl ) . 
  24.  Perez-Soler  R ,  Chachoua  A ,  Hammond  LA , et al .  Determinants of tumor 
response and survival with erlotinib in patients with non-small-cell lung 
cancer .  J Clin Oncol .  2004 ; 22 ( 16 ): 3238 – 3247 . 
  25.  Parra  HS ,  Cavina  R ,  Latteri  F , et al .  Analysis of epidermal growth factor 
receptor expression as a predictive factor for response to geﬁ tinib (‘Iressa ’ , 
ZD1839) in non-small-cell lung cancer .  Br J Cancer .  2004 ; 91 ( 2 ): 208 – 212 . 
  26.  Moroni  M ,  Veronese  S ,  Benvenuti  S , et al .  Gene copy number for epider-
mal growth factor receptor (EGFR) and clinical response to antiEGFR 
treatment in colorectal cancer: a cohort study .  Lancet Oncol .  2005 ; 6 ( 5 ): 
279 – 286 . 
  27.  Amado  RG ,  Wolf  M ,  Peeters  M , et al .  Wild-type KRAS is required for 
panitumumab efﬁ cacy in patients with metastatic colorectal cancer .  J Clin 
Oncol .  2008 ; 26 ( 10 ): 1626 – 1634 . 
  28.  Bokemeyer  C ,  Bondarenko  I ,  Makhson  A , et al .  Fluorouracil, leucovorin, 
and oxaliplatin with and without cetuximab in the ﬁ rst-line treatment of 
metastatic colorectal cancer .  J Clin Oncol .  2009 ; 27 ( 5 ): 663 – 671 . 
  29.  Van Cutsem  E ,  Köhne  CH ,  Hitre  E , et al .  Cetuximab and chemotherapy 
as initial treatment for metastatic colorectal cancer .  N Engl J Med . 
 2009 ; 360 ( 14 ): 1408 – 1417 . 
 by guest on June 1, 2015
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
1322   Review | JNCI Vol. 101, Issue 19  |  October 7, 2009
  30.  McCubrey  JA ,  Steelman  LS ,  Abrams  SL , et al .  Roles of the RAF/MEK/
ERK and PI3K/PTEN/AKT pathways in malignant transformation and 
drug resistance .  Adv Enzyme Regul .  2006 ; 46 ( 1 ): 249 – 279 . 
  31.  Bos  JL .  ras oncogenes in human cancer: a review .  Cancer Res.  1989 ; 49 ( 17 ):
 4682 – 4689 . 
  32.  Barault  L ,  Veyrie  N ,  Jooste  V , et al .  Mutations in the RAS-MAPK, PI(3)
K (phosphatidylinositol-3-OH kinase) signaling network correlate with 
poor survival in a population-based series of colon cancers .  Int J Cancer . 
 2008 ; 122 ( 10 ): 2255 – 2259 . 
  33.  Benvenuti  S ,  Sartore-Bianchi  A ,  Di Nicolantonio  F , et al .  Oncogenic 
activation of the RAS/RAF signaling pathway impairs the response of 
metastatic colorectal cancers to anti-epidermal growth factor receptor 
antibody therapies .  Cancer Res.  2007 ; 67 ( 6 ): 2643 – 2648 . 
  34.  Lievre  A ,  Bachet  JB ,  Le Corre  D , et al .  KRAS mutation status is predictive 
of response to cetuximab therapy in colorectal cancer .  Cancer Res.  2006 ;
 66 ( 8 ): 3992 – 3995 . 
  35.  Frattini  M ,  Signoroni  S ,  Pilotti  S , et al .  Phosphatase protein homologue 
to tensin expression and phosphatidylinositol-3 phosphate kinase muta-
tions in colorectal cancer .  Cancer Res.  2005 ; 65 ( 23 ): 11227 . 
  36.  Freeman  DJ ,  Juan  T ,  Reiner  M , et al .  Association of K-ras mutational 
status and clinical outcomes in patients with metastatic colorectal 
cancer receiving panitumumab alone .  Clin Colorectal Cancer .  2008 ; 7 ( 3 ): 
184 – 190 . 
  37.  Velho  S ,  Oliveira  C ,  Ferreira  A , et al .  The prevalence of PIK3CA muta-
tions in gastric and colon cancer .  Eur J Cancer .  2005 ; 41 ( 11 ): 1649 – 1654 . 
  38.  Perrone  F ,  Lampis  A ,  Orsenigo  M , et al .  PI3KCA/PTEN deregulation 
contributes to impaired responses to cetuximab in metastatic colorectal 
cancer patients .  Ann Oncol .  2009 ; 20 ( 1 ): 84 – 90 . 
  39.  Rajagopalan  H ,  Bardelli  A ,  Lengauer  C , et al .  Tumorigenesis: RAF/RAS 
oncogenes and mismatch-repair status .  Nature .  2002 ; 418 ( 6901 ): 934 . 
  40.  Di Nicolantonio  F ,  Martini  M ,  Molinari  F , et al .  Wild-type  BRAF is 
required for response to panitumumab or cetuximab in metastatic colorec-
tal cancer .  J Clin Oncol .  2008 ; 26 ( 35 ): 5705 – 5712 . 
  41.  Tol  J ,  Nagtegaal  I ,  Punt  CJA .  BRAF mutation in metastatic colorectal 
cancer [letter to editor] .  N Engl J Med .  2009 ; 361 ( 1 ): 98 – 99 . 
  42.  Fearon  ER ,  Vogelstein  B .  A genetic model for colorectal tumorigenesis . 
 Cell.  1990 ; 61 ( 5 ): 759 – 767 . 
  43.  Andreyev  HJ ,  Norman  AR ,  Cunningham  D , et al .  Kirsten ras mutations 
in patients with colorectal cancer: the ‘RASCAL II ’ study .  Br J Cancer . 
 2001 ; 85 ( 5 ): 692 – 696 . 
  44.  Zauber  P ,  Sabbath-Solitare  M ,  Marotta  SP ,  Bishop  DT .  Molecular 
changes in the Ki-ras and APC genes in primary colorectal carcinoma and 
synchronous metastases compared with the ﬁ ndings in accompanying 
adenomas .  Mol Pathol .  2003 ; 56 ( 3 ): 137 – 140 . 
  45.  Artale  S ,  Sartore-Bianchi  A ,  Veronese  S , et al .  Mutations of KRAS and 
BRAF in primary and matched metastatic sites of colorectal cancer .  J Clin 
Oncol .  2008 ; 26 ( 25 ): 4217 – 4219 . 
  46.  Etienne-Grimaldi  MC ,  Formento  JL ,  Francoual  M , et al .  K-Ras muta-
tions and treatment outcome in colorectal cancer patients receiving exclu-
sive ﬂ uoropyrimidine therapy .  Clin Cancer Res.  2008 ; 14 ( 15 ): 4830 – 4835 . 
  47.  Albanese  I ,  Scibetta  AG ,  Migliavacca  M , et al .  Heterogeneity within and 
between primary colorectal carcinomas and matched metastases as 
revealed by analysis of Ki-ras and p53 mutations .  Biochem Biophys Res 
Commun .  2004 ; 325 ( 3 ): 784 – 791 . 
  48.  Oudejans  JJ ,  Slebos  RJ ,  Zoetmulder  FA ,  Mooi  WJ ,  Rodenhuis  S . 
 Differential activation of ras genes by point mutation in human colon 
cancer with metastases to either lung or liver .  Int J Cancer .  1991 ; 49 ( 6 ): 
875 – 879 . 
  49.  Esteller  M ,  Gonzalez  S ,  Risques  RA , et al .  K-ras and p16 aberrations 
confer poor prognosis in human colorectal cancer .  J Clin Oncol .  2001 ;
 19 ( 2 ): 299 – 304 . 
  50.  Bazan  V ,  Migliavacca  M ,  Zanna  I , et al .  Speciﬁ c codon 13 K-ras mutations 
are predictive of clinical outcome in colorectal cancer patients, whereas 
codon 12 K-ras mutations are associated with mucinous histotype .  Ann 
Oncol .  2002 ; 13 ( 9 ): 1438 – 1446 . 
  51.  Markowitz  S ,  Hines  JD ,  Lutterbaugh  J , et al .  Mutant K-ras oncogenes in 
colon cancers do not predict patient’s chemotherapy response or survival . 
 Clin Cancer Res.  1995 ; 1 ( 4 ): 441 – 445 . 
  52.  Dix  BR ,  Robbins  P ,  Soong  R , et al .  The common molecular genetic altera-
tions in Dukes ’ B and C colorectal carcinomas are not short-term prog-
nostic indicators of survival .  Int J Cancer .  1994 ; 59 ( 6 ): 747 – 751 . 
  53.  Morrin  M ,  Kelly  M ,  Barrett  N ,  Delaney  P .  Mutations of Ki-ras and p53 
genes in colorectal cancer and their prognostic signiﬁ cance .  Gut .  1994 ;
 35 ( 11 ): 1627 – 1631 . 
  54.  Roth  A ,  Tejpar  S ,  Yan  P , et al .  Correlation of molecular markers in colon 
cancer with stage-speciﬁ c prognosis: results of the translational study on 
the PETACC 3 — EORTC 40993-SAKK 60-00 trial .  Presented at: 
American Society of Clinical Oncology 2009 Gastrointestinal Cancers 
Symposium, Jan 15 – 17; San Francisco, CA [abstract 288].  http :// www . asco . 
org / ASCO / Abstracts +% 26 + Virtual + Meeting / Abstracts ?& vmview = abs
t_detail_view & confID = 63 & abstractID = 10437 . Accessed July 21 . 
  55.  Karapetis  CS ,  Khambata-Ford  S ,  Jonker  DJ , et al .  K-ras mutations and 
beneﬁ t from cetuximab in advanced colorectal cancer .  N Engl J Med .  2008 ; 
359 ( 17 ): 1757 – 1765 . 
  56.  Di Fiore  F ,  Blanchard  F ,  Charbonnier  F , et al .  Clinical relevance of KRAS 
mutation detection in metastatic colorectal cancer treated by cetuximab 
plus chemotherapy .  Br J Cancer .  2007 ; 96 ( 8 ): 1166 – 1169 . 
  57.  De Roock  W ,  Piessevaux  H ,  De Schutter  J , et al .  KRAS wild-type state 
predicts survival and is associated to early radiological response in meta-
static colorectal cancer treated with cetuximab .  Ann Oncol .  2008 ; 19 ( 3 ):
 508 – 515 . 
  58.  Frattini  M ,  Saletti  P ,  Romagnani  E , et al .  PTEN loss of expression pre-
dicts cetuximab efﬁ cacy in metastatic colorectal cancer patients .  Br J 
Cancer .  2007 ; 97 ( 8 ): 1139 – 1145 . 
  59.  Khambata-Ford  S ,  Garrett  CR ,  Meropol  NJ , et al .  Expression of epiregu-
lin and amphiregulin and K-ras mutation status predict disease control in 
metastatic colorectal cancer patients treated with cetuximab .  J Clin Oncol . 
 2007 ; 25 ( 22 ): 3230 – 3237 . 
  60.  Lievre  A ,  Bachet  JB ,  Boige  V , et al .  KRAS mutations as an independent 
prognostic factor in patients with advanced colorectal cancer treated with 
cetuximab .  J Clin Oncol .  2008 ; 26 ( 3 ): 374 – 379 . 
  61.  Amgen Inc .  Data on ﬁ le .  Thousand Oaks ,  CA .  2008 . 
  62.  Moore  MJ ,  Goldstein  D ,  Hamm  J , et al .  Erlotinib plus gemcitabine com-
pared with gemcitabine alone in patients with advanced pancreatic cancer: 
a phase III trial of the National Cancer Institute of Canada Clinical Trials 
Group .  J Clin Oncol .  2007 ; 25 ( 15 ): 1960 – 1966 . 
  63.  Philip  PA ,  Benedetti  J ,  Fenoglio-Preiser  C , et al .  Phase III study of gem-
citabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with 
locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG 
S0205 study [2007 ASCO Meeting abstracts] .  J Clin Oncol .  2007 ; 25 ( 18 )
( suppl ): LBA4509 . 
  64.  Sempere  LF ,  Korc  M .  Shining the spotlight on shed KRAS in pancreatic 
cancer .  Cancer Biol Ther .  2008 ; 7 ( 3 ): 361 – 363 . 
  65.  Pao  W ,  Wang  TY ,  Riely  GJ , et al .  KRAS mutations and primary resistance 
of lung adenocarcinomas to geﬁ tinib or erlotinib .  PLoS Med .  2005 ; 2 ( 1 ): e17 . 
  66.  Massarelli  E ,  Varella-Garcia  M ,  Tang  X , et al .  KRAS mutation is an 
important predictor of resistance to therapy with epidermal growth factor 
receptor tyrosine kinase inhibitors in non-small-cell lung cancer .  Clin 
Cancer Res.  2007 ; 13 ( 10 ): 2890 – 2896 . 
  67.  Eberhard  DA ,  Johnson  BE ,  Amler  LC , et al .  Mutations in the epidermal 
growth factor receptor and in KRAS are predictive and prognostic indica-
tors in patients with non-small-cell lung cancer treated with chemotherapy 
alone and in combination with erlotinib .  J Clin Oncol .  2005 ; 23 ( 25 ): 
5900 – 5909 . 
  68.  Bianco  R ,  Shin  I ,  Ritter  CA , et al .  Loss of PTEN/MMAC1/TEP in EGF 
receptor-expressing tumor cells counteracts the antitumor action of 
EGFR tyrosine kinase inhibitors .  Oncogene .  2003 ; 22 ( 18 ): 2812 – 2822 . 
  69.  Mellinghoff  IK ,  Wang  MY ,  Vivanco  I , et al .  Molecular determinants of 
the response of glioblastomas to EGFR kinase inhibitors .  N Engl J Med . 
 2005 ; 353 ( 19 ): 2012 – 2024 . 
  70.  Nagata  Y ,  Lan  KH ,  Zhou  X , et al .  PTEN activation contributes to tumor 
inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resis-
tance in patients .  Cancer Cell.  2004 ; 6 ( 2 ): 117 – 127 . 
  71.  Jhawer  M ,  Goel  S ,  Wilson  AJ , et al .  PIK3CA mutation/PTEN expression 
status predicts response of colon cancer cells to the epidermal growth fac-
tor receptor inhibitor cetuximab .  Cancer Res.  2008 ; 68 ( 6 ): 1953 – 1961 . 
 by guest on June 1, 2015
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
jnci.oxfordjournals.org   JNCI | Review 1323
  72.  Sartore-Bianchi  A ,  Martini  M ,  Molinari  F , et al .  PIK3CA mutations in 
colorectal cancer are associated with clinical resistance to EGFR-targeted 
monoclonal antibodies .  Cancer Res.  2009 ; 69 ( 5 ): 1851 – 1857 . 
  73.  Prenen  H ,  De Schutter  J ,  Jacobs  B , et al .  PIK3CA mutations are not a 
major determinant of resistance to the epidermal growth factor receptor 
inhibitor cetuximab in metastatic colorectal cancer .  Clin Cancer Res. 
 2009 ; 15 ( 9 ): 3184 – 3188 . 
  74.  Razis  E ,  Briasoulis  E ,  Vrettou  E , et al .  Potential value of PTEN in pre-
dicting cetuximab response in colorectal cancer. An exploratory study . 
 BMC Cancer .  2008 ; 8 : 234 . 
  75.  Yuan  TL .  Cantley LC. PI3K pathway alterations in cancer: variations on 
a theme .  Oncogene .  2008 ; 27 ( 41 ): 5497 – 5510 . 
  76.  Bianco  R ,  Garofalo  S ,  Rosa  R , et al .  Inhibition of mTOR pathway by 
everolimus cooperates with EGFR inhibitors in human tumours sensi-
tive and resistant to anti-EGFR drugs .  Br J Cancer .  2008 ; 98 ( 5 ): 
923 – 930 . 
  77.  Benvenuti  S ,  Frattini  M ,  Arena  S , et al .  PIK3CA cancer mutations display 
gender and tissue speciﬁ city patterns .  Hum Mutat .  2008 ; 29 ( 2 ): 284 – 288 . 
  78.  Shia  J ,  Klimstra  DS ,  Li  AR , et al .  Epidermal growth factor receptor expres-
sion and gene ampliﬁ cation in colorectal carcinoma: an immunohistochemi-
cal and chromogenic in situ hybridization study .  Mod Pathol .  2005 ; 18 ( 10 ):
 1350 – 1356 . 
  79.  Scartozzi  M ,  Bearzi  I ,  Berardi  R , et al .  Epidermal growth factor receptor 
(EGFR) status in primary colorectal tumors does not correlate with EGFR 
expression in related metastatic sites: implications for treatment with 
EGFR-targeted monoclonal antibodies .  J Clin Oncol .  2004 ; 22 ( 23 ): 
4772 – 4778 . 
  80.  Francoual  M ,  Etienne-Grimaldi  MC ,  Formento  JL , et al .  EGFR in col-
orectal cancer: more than a simple receptor .  Ann Oncol .  2006 ; 17 ( 6 ): 
962 – 967 . 
  81.  Personeni  N ,  Hendlisz  A ,  Gallez  J , et al .  Correlation between the response 
to cetuximab alone or in combination with irinotecan and the activated/
phosphorylated epidermal growth factor receptor in metastatic colorectal 
cancer .  Semin Oncol .  2005 ; 32 ( 6 )( suppl 9 ): S59 – S62 . 
  82.  Taron  M ,  Ichinose  Y ,  Rosell  R , et al .  Activating mutations in the tyrosine 
kinase domain of the epidermal growth factor receptor are associated with 
improved survival in geﬁ tinib-treated chemorefractory lung adenocarci-
nomas .  Clin Cancer Res.  2005 ; 11 ( 16 ): 5878 – 5885 . 
  83.  Sequist  LV ,  Joshi  VA ,  Janne  PA , et al .  Response to treatment and survival 
of patients with non-small cell lung cancer undergoing somatic EGFR 
mutation testing .  Oncologist .  2007 ; 12 ( 1 ): 90 – 98 . 
  84.  Barber  TD ,  Vogelstein  B ,  Kinzler  KW ,  Velculescu  VE .  Somatic muta-
tions of EGFR in colorectal cancers and glioblastomas .  N Engl J Med . 
 2004 ; 351 ( 27 ): 2883 . 
  85.  Lenz  HJ ,  Van Cutsem  E ,  Khambata-Ford  S , et al .  Multicenter phase II 
and translational study of cetuximab in metastatic colorectal carcinoma 
refractory to irinotecan, oxaliplatin, and ﬂ uoropyrimidines .  J Clin Oncol . 
 2006 ; 24 ( 30 ): 4914 – 4921 . 
  86.  Moroni  M ,  Sartore-Bianchi  A ,  Benvenuti  S , et al .  Somatic mutation of 
EGFR catalytic domain and treatment with geﬁ tinib in colorectal cancer . 
 Ann Oncol .  2005 ; 16 ( 11 ): 1848 – 1849 . 
  87.  Press  OA ,  Zhang  W ,  Gordon  MA , et al .  Gender-related survival differ-
ences associated with EGFR polymorphisms in metastatic colon cancer . 
 Cancer Res.  2008 ; 68 ( 8 ): 3037 – 3042 . 
  88.  Goncalves  A ,  Esteyries  S ,  Taylor-Smedra  B , et al .  A polymorphism of 
EGFR extracellular domain is associated with progression free-survival in 
metastatic colorectal cancer patients receiving cetuximab-based treatment . 
 BMC Cancer .  2008 ; 8 : 169 . 
  89.  Graziano  F ,  Ruzzo  A ,  Loupakis  F , et al .  Pharmacogenetic proﬁ ling for 
cetuximab plus irinotecan therapy in patients with refractory advanced 
colorectal cancer .  J Clin Oncol .  2008 ; 26 ( 9 ): 1427 – 1434 . 
  90.  Wang  WS ,  Chen  PM ,  Chiou  TJ , et al .  Epidermal growth factor receptor 
R497K polymorphism is a favorable prognostic factor for patients with 
colorectal carcinoma .  Clin Cancer Res.  2007 ; 13 ( 12 ): 3597 – 3604 . 
  91.  Garm Spindler  KL ,  Pallisgaard  N ,  Rasmussen  AA , et al .  The importance 
of KRAS mutations and EGF61A>G polymorphism to the effect of cetux-
imab and irinotecan in metastatic colorectal cancer .  Ann Oncol .  2009 ; 20 ( 5 ): 
879 – 884 . 
  92.  Zhang  W ,  Gordon  M ,  Press  OA , et al .  Cyclin D1 and epidermal growth fac-
tor polymorphisms associated with survival in patients with advanced colorec-
tal cancer treated with cetuximab .  Pharmacogenet Genomics .  2006 ; 16 ( 7 ): 
475 – 483 . 
  93.  Ooi  A ,  Takehana  T ,  Li  X , et al .  Protein overexpression and gene ampliﬁ -
cation of HER-2 and EGFR in colorectal cancers: an immunohistochemi-
cal and ﬂ uorescent in situ hybridization study .  Mod Pathol .  2004 ; 17 ( 8 ): 
895 – 904 . 
  94.  Sartore-Bianchi  A ,  Moroni  M ,  Veronese  S , et al .  Epidermal growth factor 
receptor gene copy number and clinical outcome of metastatic colorectal 
cancer treated with panitumumab .  J Clin Oncol .  2007 ; 25 ( 22 ): 3238 – 3245 . 
  95.  Cappuzzo  F ,  Finocchiaro  G ,  Rossi  E , et al .  EGFR FISH assay predicts for 
response to cetuximab in chemotherapy refractory colorectal cancer 
patients .  Ann Oncol .  2008 ; 19 ( 4 ): 717 – 723 . 
  96.  Personeni  N ,  Fieuws  S ,  Piessevaux  H , et al .  Clinical usefulness of EGFR 
gene copy number as a predictive marker in colorectal cancer patients 
treated with cetuximab: a ﬂ uorescent in situ hybridization study .  Clin 
Cancer Res.  2008 ; 14 ( 18 ): 5869 – 5876 . 
  97.  Moroni  M ,  Sartore-Bianchi  A ,  Veronese  S ,  Siena  S .  EGFR FISH in col-
orectal cancer: what is the current reality?  Lancet Oncol .  2008 ; 9 ( 5 ):
 402 – 403 . 
  98.  Jacobs  B ,  Biesmans  B ,  De Roock  W ,  De Schutter  J ,  Van Cutsem  E ,  Tejpar  E . 
 Epiregulin and amphiregulin expression deﬁ nes a subset of colorectal 
tumors sensitive to EGFR inhibition .  In: Proceedings of the 100th Annual 
Meeting of the American Association for Cancer Research; April 18 – 22, 
2009; Denver, CO: AACR; 2009. Abstract 1346 . 
  99.  Harbison  CT ,  Mauro  DJ ,  Clark  EA ,  Khambata Ford  S .  In reply .  J Clin 
Oncol .  2008 ; 26 ( 13 ): 2230 – 2231 . 
  100.  Finocchiaro  G ,  Cappuzzo  F ,  Janne  PA , et al .  EGFR, HER2 and Kras as 
predictive factors for cetuximab sensitivity in colorectal cancer [abstract 
4021] .  J Clin Oncol .  2007 ; 25 ( suppl ). 
  101.  Folkman  J .  Angiogenesis in cancer, vascular, rheumatoid and other dis-
ease .  Nat Med .  1995 ; 1 ( 1 ): 27 – 31 . 
  102.  Ellis  LM .  Angiogenesis and its role in colorectal tumor and metastasis 
formation .  Semin Oncol .  2004 ; 31 ( 6 )( suppl 17 ): 3 – 9 . 
  103.  Ellis  LM .  Epidermal growth factor receptor in tumor angiogenesis . 
 Hematol Oncol Clin North Am.  2004 ; 18 ( 5 ): 1007 – 1021 . 
  104.  Ciardiello  F ,  Troiani  T ,  Bianco  R , et al .  Interaction between the epider-
mal growth factor receptor (EGFR) and the vascular endothelial growth 
factor (VEGF) pathways: a rational approach for multi-target anticancer 
therapy .  Ann Oncol .  2006 ; 17 ( suppl 7 ): vii109 – vii114 . 
  105.  Ciardiello  F ,  Bianco  R ,  Caputo  R , et al .  Antitumor activity of ZD6474, a 
vascular endothelial growth factor receptor tyrosine kinase inhibitor, in 
human cancer cells with acquired resistance to antiepidermal growth fac-
tor receptor therapy .  Clin Cancer Res.  2004 ; 10 ( 2 ): 784 – 793 . 
  106.  Tortora  G ,  Ciardiello  F ,  Gasparini  G .  Combined targeting of EGFR-
dependent and VEGF-dependent pathways: rationale, preclinical studies 
and clinical applications .  Nat Clin Pract Oncol .  2008 ; 5 ( 9 ): 521 – 530 . 
  107.  Bianco  R ,  Rosa  R ,  Damiano  V , et al .  Vascular endothelial growth factor 
receptor-1 contributes to resistance to anti-epidermal growth factor 
receptor drugs in human cancer cells .  Clin Cancer Res.  2008 ; 14 ( 16 ): 
5069 – 5080 . 
  108.  Vallböhmer  D ,  Zhang  W ,  Gordon  M , et al .  Molecular determinants of 
cetuximab efﬁ cacy .  J Clin Oncol .  2005 ; 23 ( 15 ): 3536 – 3544 . 
  109.  Nagashima  F ,  Zhang  W ,  Gordon  M , et al .  EGFR, Cox-2, and EGF poly-
morphisms associated with progression-free survival of EGFR-expressing 
metastatic colorectal cancer patients treated with single-agent cetuximab 
(IMCL-0144) [abstract 4129] .  J Clin Oncol .  2007 ; 25 ( suppl ). 
  110.  Wang  XQ ,  Li  H ,  Van Putten  V ,  Winn  RA ,  Heasley  LE ,  Nemenoff  RA . 
 Oncogenic K-Ras regulates proliferation and cell junctions in lung epithe-
lial cells through induction of cyclooxygenase-2 and activation of metallo-
proteinase-9 .  Mol Biol Cell.  2009 ; 20 ( 3 ): 791 – 800 . 
  111.  Smakman  N ,  Kranenburg  O ,  Vogten  JM ,  Bloemendaal  AL ,  van Diest  P , 
 Borel Rinkes  IH .  Cyclooxygenase-2 is a target of KRASD12, which facili-
tates the outgrowth of murine C26 colorectal liver metastases .  Clin Cancer 
Res.  2005 ; 11 ( 1 ): 41 – 48 . 
  112.  Pai  R ,  Soreghan  B ,  Szabo  IL ,  Pavelka  M ,  Baatar  D ,  Tarnawski  AS . 
 Prostaglandin E2 transactivates EGF receptor: a novel mechanism for 
 by guest on June 1, 2015
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
1324   Review | JNCI Vol. 101, Issue 19  |  October 7, 2009
promoting colon cancer growth and gastrointestinal hypertrophy .  Nat 
Med .  2002 ; 8 ( 3 ): 289 – 293 . 
  113.  Scartozzi  M ,  Bearzi  I ,  Pierantoni  C , et al .  Nuclear factor-kB tumor expres-
sion predicts response and survival in irinotecan-refractory metastatic 
colorectal cancer treated with cetuximab-irinotecan therapy .  J Clin Oncol . 
 2007 ; 25 ( 25 ): 3930 – 3935 . 
  114.  Zhang  W ,  Gordon  M ,  Schultheis  AM , et al .  FCGR2A and FCGR3A 
polymorphisms associated with clinical outcome of epidermal growth fac-
tor receptor expressing metastatic colorectal cancer patients treated with 
single-agent cetuximab .  J Clin Oncol .  2007 ; 25 ( 24 ): 3712 – 3718 . 
  115.  Bibeau  F ,  Lopez-Crapez  E ,  Di Fiore  F , et al .  Impact of Fc{gamma}RIIa-
Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical 
outcome of patients with metastatic colorectal cancer treated with cetux-
imab plus irinotecan .  J Clin Oncol .  2009 ; 27 ( 7 ): 1122 – 1129 . 
  116.  Negri  F ,  Musolino  A ,  Naldi  N , et al .  Immunoglobulin G fragment C 
receptor polymorphisms and clinical outcome of EGFR-expressing meta-
static colorectal cancer patients treated with cetuximab-based therapy. 
Abstract presented at: 14th ECCO; September 23 – 27, 2007; Barcelona, 
Spain .  Eur J Cancer .  2007 ; 5 ( 4 suppl ): 96 . 
  117.  Lopez-Albaitero  A ,  Ferris  RL .  Immune activation by epidermal growth 
factor receptor speciﬁ c monoclonal antibody therapy for head and neck 
cancer .  Arch Otolaryngol Head Neck Surg .  2007 ; 133 ( 12 ): 1277 – 1281 . 
  118.  Oden-Gangloff  A ,  Di Fiore  F ,  Bibeau  F , et al .  TP53 mutations predict 
disease control in metastatic colorectal cancer treated with cetuximab-
based chemotherapy .  Br J Cancer .  2009 ; 100 ( 8 ): 1330 – 1335 . 
  119.  Herbst  RS ,  Prager  D ,  Hermann  R , et al .  TRIBUTE: a phase III trial of 
erlotinib hydrochloride (OSI-774) combined with carboplatin and pacli-
taxel chemotherapy in advanced non-small-cell lung cancer .  J Clin Oncol . 
 2005 ; 23 ( 25 ): 5892 – 5899 . 
  120.  Berlin  J ,  Van Cutsem  E ,  Peeters  M , et al .  Predictive value of skin toxicity 
severity for response to panitumumab in patients with metastatic colorec-
tal cancer (mCRC): a pooled analysis of ﬁ ve clinical trials [abstract 4134] . 
 J Clin Oncol .  2007 ; 25 ( suppl ). 
  121.  Tejpar  S ,  Peeters  M ,  Humblet  Y , et al .  Phase I/II study of cetuximab dose-
escalation in patients with metastatic colorectal cancer (mCRC) with no or 
slight skin reactions on cetuximab standard dose treatment (EVEREST): 
pharmacokinetic (PK), pharmacodynamic (PD) and efﬁ cacy data [abstract 
4037] .  J Clin Oncol .  2007 ; 25 ( suppl ). 
  122.  Tejpar  S ,  Peeters  M ,  Humblet  Y , et al .  Relationship of efﬁ cacy with KRAS 
status (wild type versus mutant) in patients with irinotecan-refractory 
metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and 
escalating doses of cetuximab (q1w): the EVEREST experience (prelimi-
nary data) [abstract 4001] .  J Clin Oncol .  2008 ; 26 ( suppl ). 
  123.  Rowinsky  EK ,  Schwartz  GH ,  Gollob  JA , et al .  Safety, pharmacokinetics, 
and activity of ABX-EGF, a fully human anti-epidermal growth factor 
receptor monoclonal antibody in patients with metastatic renal cell cancer . 
 J Clin Oncol .  2004 ; 22 ( 15 ): 3003 – 3015 . 
  124.  Perez-Soler  R ,  Saltz  L .  Cutaneous adverse effects with HER1/EGFR-
targeted agents: is there a silver lining?  J Clin Oncol .  2005 ; 23 ( 22 ): 
5235 – 5246 . 
  125.  Allan  DGP .  Nimotuzumab: evidence of clinical beneﬁ t without rash . 
 Oncologist .  2005 ; 10 ( 9 ): 760 – 761 . 
  126.  Crombet  T ,  Osorio  M ,  Cruz  T , et al .  Use of the humanized anti-epidermal 
growth factor receptor monoclonal antibody h-R3 in combination with 
radiotherapy in the treatment of locally advanced head and neck cancer 
patients .  J Clin Oncol .  2004 ; 22 ( 9 ): 1646 – 1654 . 
  127.  Tejpar  S ,  Piessevaux  H ,  Claes  K , et al .  Magnesium wasting associated 
with epidermal-growth factor receptor-targeting antibodies in colorectal 
cancer: a prospective study .  Lancet Oncol .  2007 ; 85 ( 5 ): 387 – 394 . 
  128.  Vincenzi  B ,  Santini  D ,  Galluzzo  S , et al .  Early magnesium reduction in 
advanced colorectal cancer patients treated with cetuximab plus irinotecan 
as predictive factor of efﬁ cacy and outcome .  Clin Cancer Res.  2008 ;
 14 ( 13 ): 4219 – 4224 . 
  129.  Vincenzi  B ,  Santini  D ,  Russo  A , et al .  Angiogenesis modiﬁ cations related 
with cetuximab plus irinotecan as anticancer treatment in advanced col-
orectal cancer patients .  Ann Oncol .  2006 ; 17 ( 5 ): 835 – 841 . 
  130.  Anonymous .  Summary of product characteristics (Vectibix) . 
 http :// www . emea . europa . eu / humandocs / PDFs / EPAR / vectibix / H - 741 -
 PI - en . pdf . Accessed July 21, 2009 . 
  131.  Allegra  CJ ,  Jessup  JM ,  Somerﬁ eld  MR , et al .  American Society of Clinical 
Oncology provisional clinical opinion: testing for KRAS gene mutations 
in patients with metastatic colorectal carcinoma to predict response to 
anti-epidermal growth factor receptor monoclonal antibody therapy . 
 J Clin Oncol .  2009 ; 27 ( 12 ): 2091 – 2096 . 
  132.  Di Nicolantonio  F ,  Sartore-Bianchi  A ,  Molinari  F , et al .  BRAF, PIK3CA, 
and KRAS mutations and loss of PTEN expression impair response to 
EGFR-targeted therapies in metastatic colorectal cancer .  In: Proceedings 
of the 100th Annual Meeting of the American Association for Cancer 
Research; April 18 – 22, 2009; Denver, CO: AACR; 2009. Abstract LB-93 . 
  133.  Razis  E ,  Briasoulis  E ,  Kostopoulos  I , et al.  Predictive markers for the 
treatment of colorectal cancer with cetuximab [O Meeting abstract 
13500] .  J Clin Oncol .  2006 ; 24 ( 18 )( suppl ) . 
  134.  European Medicines Agency .  Committee for Medicinal Products for 
Human Use December 2007 Plenary Meeting monthly report .  http :// www .
 emea . europa . eu / pdfs / human / press / pr / 58563707en . pdf. Accessed July 21, 
2009 . 
  135.  Siena  S ,  Peeters  M ,  Van Cutsem  E , et al .  Association of progression-free 
survival with patient-reported outcomes and survival: results from a ran-
domised phase 3 trial of panitumumab .  Br J Cancer .  2007 ; 97 ( 11 ): 
1469 – 1474 . 
  136.  European Medicines Agency .  Committee for Medicinal Products for 
Human Use May 2008 Plenary Meeting monthly report .  http :// www .
 emea . europa . eu / pdfs / human / press / pr / 27923508en . pdf . Accessed July 21, 
2009 . 
  137.  Anonymous .  FDA adds KRAS testing info to Vectibix, Erbitux Labels 
(Press Release, Genome Web News) .  http :// www . genomeweb . com / dxpgx 
/ fda - adds - kras - testing - info - vectibix - erbitux - labels . Accessed July 21, 
2009 . 
  138.  Baker  J ,  Dutta  D ,  Watson  D , et al .  Evaluation of tumor gene expression 
and K-Ras mutations in FFPE tumor tissue as predictors of response to 
cetuximab in metastatic colorectal cancer [abstract 3512] .  J Clin Oncol . 
 2008 ; 26 ( suppl ). 
  139.  Sharma  SV ,  Bell  DW ,  Settleman  J ,  Haber  DA .  Epidermal growth factor 
receptor mutations in lung cancer .  Nat Rev Cancer .  2007 ; 7 ( 3 ): 169 – 181 . 
  140.  Wheeler  DL ,  Huang  S ,  Kruser  TJ , et al .  Mechanisms of acquired resis-
tance to cetuximab: role of HER (ErbB) family members .  Oncogene . 
 2008 ; 27 ( 28 ): 3944 – 3956 . 
 Funding 
 Funding for the writing of this manuscript was provided by  Amgen (Europe) 
GmbH , Zug, Switzerland. This work was partly supported by grants from 
 Oncologia Ca ’ Granda Onlus Fondazione ,  Associazione Italiana Ricerca Cancro , 
 Italian Ministry of Health ,  Regione Piemonte ,  EU FP6 MSCs contract 037297, 
 EU FP7 Marie Curie , contract n 218071,  CRT Progetto Alﬁ eri . Amgen (Europe) 
GmbH had the opportunity to review the manuscript for accuracy. 
 Notes 
 J. Balfour was an employee of Amgen at the time that writing of this article com-
menced. She is currently a self-employed medical writer. 
 The authors had full responsibility for identiﬁ cation of articles, analysis and 
interpretation of the data, writing of the manuscript, and the decision to submit 
the manuscript for publication. 
 S. Siena, A. Sartore-Bianchi, A. Bardelli, and F. Di Nicolantonio have no 
ﬁ nancial interests, arrangements, or connections to declare. 
 Manuscript received  November  21 ,  2008 ; revised  July  17 ,  2009 ; accepted 
 July  24 ,  2009 . 
 by guest on June 1, 2015
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
